Turner Investments’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Turner Investments’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-50,000	Closed	-$515K	–	283
2016 Q4	$515K	Buy	+50,000	New	+$457K	0.21%	146
2015 Q3	–	Sell	-140,620	Closed	-$2.09M	–	302
2015 Q2	$2.09M	Sell	140,620 -10,535	-7%	-$160K	0.38%	86
2015 Q1	$2.29M	Buy	151,155 +70,960	+88%	+$990K	0.41%	80
2014 Q4	$1.07M	Sell	80,195 -95,175	-54%	-$1.23M	0.13%	262
2014 Q3	$2.21M	Buy	+175,370	New	+$1.7M	0.13%	227

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Turner Investments's CNCE Position: Q1 2017 in Review

Turner Investments sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017, closing a stake of 50,000 shares — an estimated $515K sold.

Turner Investments first reported a position in CNCE in Q3 2014 and held it in 5 quarters. The position peaked at $2.29M in Q1 2015. 85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

Turner Investments reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Turner Investments sold 50,000 Concert Pharmaceuticals, Inc. shares in Q1 2017, an estimated $515K.
Turner Investments first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and held it in 5 quarters.
Turner Investments's Concert Pharmaceuticals, Inc. position peaked at $2.29M in Q1 2015.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on Turner Investments's 13F filing for Q1 2017, filed 11 May 2017.